lutetium has been researched along with Lung Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Akhmetova, DR; Antuganov, D; Bukreeva, AS; Karpov, TE; Kuznetsova, DS; Muslimov, AR; Postovalova, AS; Rodimova, SA; Rogova, AS; Timin, AS; Zyuzin, MV | 1 |
| Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M | 1 |
| Abergel, RJ; An, DD; Ansoborlo, C; Gauny, SS; Karsunky, H; Lakes, AL; Liang, BH; McKnight, KD; Rees, JA | 1 |
| Cho, EH; Chung, C; Dho, SH; Jung, SH; Kim, JY; Kim, LK; Kim, SY; Lee, J; Lee, SY; Lim, JC; Min, SW | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| Feron, O; Gallez, B; Lucas, S; Masereel, B; Michiels, C; Vander Borght, T | 1 |
| Geramifar, P; Kamali Asl, A; Khazaee Moghadam, M; Zaidi, H | 1 |
| Inoue, T; Kawano, T; Ohtake, E | 1 |
| Agazzi, A; Aricò, D; Bodei, L; De Cicco, C; De Simone, M; Pacifici, M; Paganelli, G; Quarna, J; Sansovini, M; Sierra, ML | 1 |
| Comans, EF; Hoekstra, OS; Joshi, U; Pijpers, R; Raijmakers, PG; Teule, GJ; van Lingen, A | 1 |
| Bakker, WH; de Herder, WW; Feelders, RA; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; van Essen, M; Wolbers, JG | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Carrasquillo, JA; Chung, Y; Curt, G; Feuerstein, I; Milenic, DE; Mulligan, T; Paik, C; Perentesis, P; Reynolds, J; Schlom, J | 1 |
| Chen, S; Goldenberg, DM; Govindan, SV; Griffiths, GL; Hansen, HJ; Reed, L; Richel, H; Stein, R | 1 |
3 trial(s) available for lutetium and Lung Neoplasms
| Article | Year |
|---|---|
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage | 1995 |
11 other study(ies) available for lutetium and Lung Neoplasms
| Article | Year |
|---|---|
Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer.
Topics: Animals; Calcium Carbonate; Cell Line, Tumor; Lung Neoplasms; Lutetium; Mice; Radioisotopes; Tissue Distribution | 2022 |
Evaluating
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Benzodiazepines; Beta Particles; Female; HEK293 Cells; Humans; Immunoconjugates; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Lutetium; Maximum Tolerated Dose; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Radioisotopes; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; CD55 Antigens; Cell Line, Tumor; Humans; Isotope Labeling; Lung Neoplasms; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Pleural Neoplasms; Radioimmunotherapy; Radioisotopes; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2018 |
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
Topics: Algorithms; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Iodine Radioisotopes; Lung; Lung Neoplasms; Lutetium; Models, Statistical; Monte Carlo Method; Nanomedicine; Neoplasms; Radiation Pneumonitis; Radioimmunotherapy; Radioisotopes; Radiotherapy Planning, Computer-Assisted; Rhenium; Yttrium Radioisotopes | 2015 |
Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
Topics: Algorithms; Bone Neoplasms; Computer Simulation; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Monte Carlo Method; Organ Specificity; Phosphorus Radioisotopes; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Planning, Computer-Assisted; Water; Yttrium Radioisotopes | 2016 |
Deep-inspiration breath-hold PET/CT of lung cancer: maximum standardized uptake value analysis of 108 patients.
Topics: Aged; Artifacts; Female; Fluorodeoxyglucose F18; Humans; Inhalation; Lung Neoplasms; Lutetium; Male; Middle Aged; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Silicates; Subtraction Technique; Tomography, X-Ray Computed | 2008 |
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
Topics: Adult; Aged; B-Lymphocytes; Colonic Neoplasms; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Lung Neoplasms; Lutetium; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Yttrium Radioisotopes | 2009 |
Evaluation of pulmonary nodules: comparison of a prototype dual crystal (LSO/NAI) dual head coincidence camera and full ring positron emission tomography (PET).
Topics: Aged; Algorithms; Female; Gamma Cameras; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lutetium; Male; Positron-Emission Tomography; Prospective Studies; Silicates; Solitary Pulmonary Nodule; Statistics, Nonparametric | 2005 |
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals | 2006 |
Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Topics: Animals; Antibodies, Monoclonal; Female; Glycoproteins; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Lung Neoplasms; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2001 |